Lansovil 30 Junior Tablet DT contains Lansoprazole 30 mg, a proton pump inhibitor indicated for the treatment of acid-related gastrointestinal conditions in pediatric patients. Lansoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. This medication is primarily used for the management of gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome in children. Lansovil 30 Junior Tablet DT is formulated as a dispersible tablet, facilitating ease of administration and improved compliance in pediatric populations who may have difficulty swallowing conventional tablets. The rapid onset of action and sustained acid suppression provided by Lansoprazole contribute to symptom relief and mucosal healing. It is important to administer the tablet before meals for optimal efficacy. Lansoprazole is generally well tolerated; however, potential adverse effects include headache, abdominal pain, diarrhea, and nausea. Long-term use should be monitored due to risks such as vitamin B12 deficiency and hypomagnesemia. Lansovil 30 Junior Tablet DT should be used under medical supervision, with dosage adjustments based on clinical response and patient weight. It is contraindicated in patients with known hypersensitivity to Lansoprazole or other proton pump inhibitors.